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Abstract
A Body Shape Index (ABSI) was specifically developed as a transformation of waist circum-
ference (WC), statistically independent of BMI to better evaluate the relative contribution of
WC to central obesity and clinical outcomes. Previous studies have found ABSI is associated
with total mortality and cardiovascular events. However, no study has specifically evaluated
the joint contribution of ABSI and BMI to cardio-metabolic outcomes (high triglycerides, low
HDL, high fasting glucose and high blood pressure). With this aim, we performed a retrospec-
tive study on 6081 Caucasian adults. Subjects underwent a medical interview, anthropomet-
ric measurements, blood sampling, measurement of blood pressure, and measurement of
visceral abdominal fat thickness (VAT) by ultrasound. Generalized linear models (GLM) were
used to evaluate the sex and age adjusted association of ABSI with binary and continuous
cardio-metabolic risk factors. Four pre-specified GLM were evaluated for each outcome:
M1 = ABSI, BMI and ABSI*BMI interaction, M2 = ABSI and BMI, M3 = ABSI alone and M4 =
BMI alone. Bayesian Information Criterion (BIC) was calculated and used to identify the best
predictive model. ABSI and BMI contributed independently to all outcomes. Compared to
BMI alone, the joint use of BMI and ABSI yielded significantly improved associations for hav-
ing high triglycerides (BIC = 5261 vs. 5286), low HDL (BIC = 5371 vs. 5381), high fasting glu-
cose (BIC = 6328 vs. 6337) but not high blood pressure (BIC = 6580 vs. 6580). The joint use
of BMI and ABSI was also more strongly associated with VAT than BMI alone (BIC = 22930
vs. 23479). In conclusion, ABSI is a useful index for evaluating the independent contribution
of WC, in addition to that of BMI, as a surrogate for central obesity on cardio-metabolic risk.
Introduction
A Body Shape Index (ABSI) is calculated by dividing waist circumference (WC) by its estimate
obtained from allometric regression of weight and height [1]. ABSI was designed to be minimally
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associated with weight, height and body mass index (BMI) so that it can be used together with
BMI to disentangle the independent contribution of WC and BMI to cardio-metabolic outcomes
[1–3].
ABSI is a predictor of total mortality, as reported by several cohort observational studies
with follow-ups ranging from 5 to 25 years [1, 4–7]. ABSI also predicts incident cardiovascular
disease (CVD) [8] with an accuracy similar to that of common laboratory measurements [9].
The fact that ABSI predicts CVD and mortality suggests that it has some potential for being
incorporated into clinical guidelines in place of WC and together with BMI [10, 11]. The
advantage of ABSI over WC is that, by design, it allows to establish the separate contribution
of BMI and the so adjusted WC to morbidity and mortality.
There is, however, limited research on the association of ABSI with established cardio-met-
abolic disease (CMD) risk factors. In one study, ABSI was positively associated with serum
insulin and C-reactive protein in men [12]. Some studies have found that ABSI was less
strongly associated than BMI with established CVD risk factors [13–15]. However, very few
studies have evaluated the joint contribution of BMI and ABSI to CMD risk factors. This is
important because the very reason why ABSI was developed was to allow researchers to deter-
mine the separate contribution of BMI and the so adjusted WC to disease.
Studies of body composition have shown that ABSI is positively associated with fat mass
and negatively associated with fat-free mass [16]. Also, in patients with type 2 diabetes mellitus,
ABSI is positively associated with visceral fat [17]. The metabolic syndrome (MS) is positively
associated with visceral fat [18–21] and negatively associated with muscle mass and gluteo-
femoral fat [22, 23]. There are presently no data on the association of ABSI with MS and its
components, i.e. high triglycerides, low HDL cholesterol, high blood pressure and high fasting
glucose.
We performed a retrospective study of a large sample of Caucasian adults to quantify the
separate and joint contribution of ABSI to MS components [18] and visceral abdominal tissue
thickness (VAT), independently of sex, age and BMI.
Materials and methods
Study design
6081 consecutive Caucasian subjects (4384 women, 72%) were retrospectively studied at Inter-
national Center for the Assessment of Nutritional Status (ICANS), University of Milan, between
September 2010 and June 2015. All subjects were enrolled because of their interest to undergo a
structured nutritional assessment. Criteria for inclusion into the study were: 1) age 18 years;
2) body mass index (BMI) 18.5 kgm-2. Exclusion criteria were: having acute infective, neuro-
logical, gastrointestinal, cardiac, renal and pulmonary disorders [24], use of medications known
to cause lipodystrophy such as steroids, other immunosuppressive and anti-retroviral agents,
and presence of scars in the measurement area of VAT [25]. On the same morning, the fasting
subjects underwent a medical interview, an anthropometric assessment, a measurement of
blood pressure, an abdominal ultrasonography (US), and blood sampling. The study was per-
formed in accordance with the Declaration of Helsinki and the subjects gave their written
informed consent. The study procedures were approved by the Ethical Committee of Milan
University.
Anthropometric and clinical assessment
Weight and height were measured following international guidelines [26]. BMI was calculated
and obesity was classified following the NIH guidelines [27]. WC was measured at the mid-
point between the last rib and the iliac crest. ABSI (m11/6 kg-2/3) and its standard deviation
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score (SDS) were calculated using the following formula:
ABSI ¼
WC
BMI2=3 Height1=2
: ð1Þ
Resting blood pressure was measured twice in sitting position after participants had rested for
at least five minutes following the JNC-7 guidelines [28].
Abdominal ultrasonography
Abdominal US was performed by the same operator using a Logiq 3 Pro instrument equipped
with a 3.5 MHz convex-array probe (GE Healthcare, Milwaukee, WI, USA). VAT, defined as
the distance between the anterior wall of the aorta and the posterior surface of the rectus abdo-
minis muscle, was measured 1 cm above the umbilicus at end-expiration [29]. The VAT mea-
surement was performed three times and the mean of the three measures was used for analysis.
The within-day intra-operator coefficient of variation (CV) for repeated measures of VAT at
ICANS is 0.8% [25, 30, 31].
Laboratory assessment
Fasting blood samples were drawn between 8:30 and 9:00 AM and analyzed in the same morn-
ing at the ICANS internal laboratory. Glucose, triglycerides, total cholesterol, HDL-cholesterol
and LDL-cholesterol were measured by means of an enzymatic method (Cobas Integra 400
Plus, Roche Diagnostics, Rotkreuz, Switzerland) with intra-and inter-assay CV < 2% [32].
Metabolic syndrome
MS was diagnosed using the harmonized international definition [18]. In detail, high WC was
defined as WC 102 cm in men and 88 cm in women; low HDL as HDL< 1.04 mmolL-1 in
men and< 1.29 mmolL-1 in women; high triglycerides as triglycerides 1.7 mmolL-1 or treat-
ment with triglycerides-lowering drugs, high blood pressure as systolic blood pressure 130
mmHg or diastolic blood pressure 85 mmHg or treatment with pressure lowering drugs, and
high glucose as glucose 5.6 mmolL-1 or treatment with glucose-lowering drugs, and MS as
3 of the above.
Statistical analysis
Most continuous variables were not Gaussian-distributed and all are reported as 50th, 25th and
75th percentiles. Categorical variables are reported as numbers and proportions. We evaluated
the association of ABSI with the binary outcomes (high triglycerides, low HDL, high blood
pressure and high fasting glucose; 0 = no, 1 = yes) and the continuous outcome (VAT, cm)
using generalized linear models (GLM). The GLM had a binomial family and a logit link for
the binary outcomes and a Gaussian family and an identity link for the continuous outcome
[33]. Four pre-specified GLM were evaluated for each outcome with the following combina-
tions of predictors:
1. ABSI (continuous, SDS), BMI (discrete, 0 = normal weight; 1 = overweight; 2 = class 1 obe-
sity; 3 = class 2 obesity; 4 = class 3 obesity), ABSIBMI interaction (continuous X discrete),
sex (discrete; 0 = female; 1 = male), age (discrete, 0 = 19 to 29 years; 1 = 30 to 39 years;
2 = 40 to 49 years; 3 = 50 to 59 years; 4 = 60 to 69 years; 5 = 70 to 76 years).
2. same as #1 without the ABSIBMI interaction.
3. same as #2 without BMI.
ABSI and cardio-metabolic risk factors
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4. same as #2 without ABSI.
Model #1 tests the joint contribution of ABSI and BMI if ABSI and BMI do interact, taking
into account the effect of sex and age. Model #2 tests the joint contribution of ABSI and BMI if
no interaction is present, taking into account the effect of sex and age. Model #3 evaluates the
effect of ABSI alone, taking into account the effect of sex and age. Lastly, Model #4 evaluates
the effect of BMI alone, taking into account the effect of sex and age. Standard diagnostics of
model fit for GLM were used and the Bayesian information criterion (BIC) was calculated [33,
34] and used to perform a relative comparison of the models. “Weak evidence” in favor of the
model with the lower BIC is said to exist when the BIC difference (ΔBIC) is2; “positive evi-
dence” when 6> ΔBIC> 2; “strong evidence” when 6 ΔBIC< 10; and “very strong evi-
dence” when ΔBIC 10 [34]. Effects plots were obtained for each model at pre-specified
values of ABSI SDS (5th, 25th, 50th, 75th and 95th internal percentiles) to allow a clinically mean-
ingful interpretation of the results [33]. Statistical analysis was performed using Stata 14.2
(Stata Corporation, College Station, TX, USA).
Results
Table 1 gives the anthropometric and laboratory measurements of the subjects. The median
BMI was 28.0 kgm-2 in women and 30.3 kgm-2 in men. The median SDS of ABSI in this pop-
ulation corresponds to the 40th NHANES 1999–2004 percentile in women and to the 53th
NHANES percentile in men [1, 2].
Table 2 gives the distribution of age, body mass index and MS and its components. 20.3%
of the subjects had normal weight, 39.7% were overweight, 27.4% had class 1 obesity, 9.9% had
class 2 obesity, and 2.6% had class 3 obesity. High waist circumference was detected in 63.6%
Table 1. Measurements of the study subjects.
Women (n = 4384) Men (n = 1697) Total (n = 6081)
P50 P25 P75 P50 P25 P75 P50 P25 P75
Age (years) 46 38 56 47 39 56 47 38 56
Weight (kg) 72.8 64.9 82.6 93 84.2 104 78.1 67.7 90.5
Height (m) 1.61 1.57 1.66 1.75 1.71 1.79 1.64 1.59 1.71
BMI (kg m-2) 28 24.9 31.7 30.3 27.7 33.3 28.7 25.6 32.3
BMI (SDS NHANES) -0.09 -0.52 0.48 0.38 -0.12 0.98 0.04 -0.43 0.64
ABSI (m11/6 kg-2/3) 0.08 0.08 0.08 0.08 0.08 0.09 0.08 0.08 0.08
ABSI (SDS NHANES) -0.25 -0.81 0.27 0.08 -0.46 0.64 -0.16 -0.73 0.38
Waist circumference (cm) 92 84 101 106 99.1 115 96 86.8 106
VAT (cm) 4.2 3 5.8 7.5 5.6 9.3 4.9 3.4 7.2
Glucose (mmol l-1) 5.11 4.77 5.44 5.44 5.11 5.94 5.16 4.83 5.61
Triglycerides (mmol l-1) 0.95 0.71 1.3 1.34 0.96 1.91 1.04 0.77 1.47
Cholesterol (mmol l-1) 5.46 4.82 6.15 5.43 4.76 6.15 5.46 4.81 6.15
LDL (mmol l-1) 3.34 2.77 3.96 3.57 2.95 4.16 3.39 2.82 4.03
HDL (mmol l-1) 1.63 1.4 1.89 1.22 1.03 1.42 1.5 1.27 1.78
Systolic blood pressure (mm Hg) 120 110 130 130 120 140 120 110 130
Diastolic blood pressure (mm Hg) 80 70 80 80 80 90 80 70 85
Abbreviations: P50 = 50th percentile (median); P25 = 25th percentile; P75 = 75th percentile; BMI = body mass index; ABSI = a body shape index;
SDS = standard deviations scores; VAT = visceral adipose tissue; LDL = low-density lipoprotein; HDL = high-density lipoprotein. Conversion factors:
Triglycerides: mg/dL = 89 * mmol/L; Total, HDL and LDL cholesterol: mg/dL = 38.67 * mmol/L; Glucose: mg/dL = 18 * mmol/L
https://doi.org/10.1371/journal.pone.0185013.t001
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Table 2. Distribution of age, body mass index and the metabolic syndrome and its components in the study subjects.
Women Men Total
N % N % N %
Age
19 to 29 years 428 9.8 101 6 529 8.7
30 to 39 years 859 19.6 330 19.4 1189 19.6
40 to 49 years 1313 29.9 533 31.4 1846 30.4
50 to 59 years 1042 23.8 410 24.2 1452 23.9
60 to 69 years 585 13.3 256 15.1 841 13.8
70 to 76 years 157 3.6 67 3.9 224 3.7
BMI NIH classification
Normal weight 1108 25.3 126 7.4 1234 20.3
Overweight 1748 39.9 669 39.4 2417 39.7
Class 1 obesity 1037 23.7 631 37.2 1668 27.4
Class 2 obesity 384 8.8 218 12.8 602 9.9
Class 3 obesity 107 2.4 53 3.1 160 2.6
High waist circumference
No 1637 37.3 574 33.8 2211 36.4
Yes 2747 62.7 1123 66.2 3870 63.6
High triglycerides
No 3876 88.4 1145 67.5 5021 82.6
Yes 508 11.6 552 32.5 1060 17.4
Triglyceride lowering drugs
No 4359 99.4 1673 98.6 6032 99.2
Yes 25 0.6 24 1.4 49 0.8
High triglycerides OR triglyceride-lowering drugs
No 3857 88 1130 66.6 4987 82
Yes 527 12 567 33.4 1094 18
Low HDL
No 3715 84.7 1330 78.4 5045 83
Yes 669 15.3 367 21.6 1036 17
High blood pressure
No 2822 64.4 567 33.4 3389 55.7
Yes 1562 35.6 1130 66.6 2692 44.3
Blood pressure lowering drugs
No 3726 85 1230 72.5 4956 81.5
Yes 658 15 467 27.5 1125 18.5
High blood pressure OR blood pressure-lowering drugs
No 2607 59.5 468 27.6 3075 50.6
Yes 1777 40.5 1229 72.4 3006 49.4
High fasting glucose
No 3409 77.8 929 54.7 4338 71.3
Yes 975 22.2 768 45.3 1743 28.7
Glucose lowering drugs
No 4355 99.3 1654 97.5 6009 98.8
Yes 29 0.7 43 2.5 72 1.2
High blood glucose OR glucose-lowering drugs
No 3404 77.6 927 54.6 4331 71.2
Yes 980 22.4 770 45.4 1750 28.8
(Continued )
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of all subjects, high triglycerides in 17.4%, low HDL in 17.0%, high blood pressure in 44.3%
and high fasting glucose in 28.7%. MS was present in 27.0% of the subjects.
Tables 3–6 give the regression coefficients and BIC for the 4 GLM used to investigate the
association between the outcomes of interest (high triglycerides, low HDL, high blood pressure
and high fasting glucose) and ABSI. The full models (models A1 to D1) allowed to explore the
existing interaction between ABSI and BMI in the prediction of the outcomes of interest. No
ABSIBMI interaction was detected for high triglycerides (model A1) and blood pressure
(model C1), whereas such interaction was present for low HDL (model B1) and, to a lesser
extent, for high glucose (model D1). ABSI and BMI contributed independently to all outcomes,
even when the interaction was not accounted for (models A2 to D2). ABSI alone, when BMI
was not included in the models (models A3 to D3) provided the weakest prediction of all out-
comes of interest. Compared to BMI alone (models A4 to D4), the joint use of BMI and ABSI
was more strongly associated with the probability of having high triglycerides (BIC = 5261 for
model A2 vs. 5286 for model A4), low HDL (BIC = 5371 for model B2 vs. 5381 for model B4),
high fasting glucose (BIC = 6328 for model D2 vs. 6337 for model D4) but not high blood pres-
sure (BIC = 6580 for model C2 vs. 6580 for model C4).
S1–S4 Figs give the effects plots corresponding to models A2, B1, C2 and D1. These figures
show the joint effects of BMI and ABSI taking into account their interaction when significant.
Table 7 gives the regression coefficients and AIC for the 4 GLM used to investigate the asso-
ciation between VAT and ABSI. ABSI and BMI contributed independently to VAT (model E1)
and there was a clear ABSIBMI interaction (model E1). Compared to BMI alone, the joint use
of BMI and ABSI was more strongly associated with VAT (AIC = 22788 for model E1 vs. 23412
for model E2).
S5 Fig gives the effects plots corresponding to model E1. This figure shows the joint effects
of BMI and ABSI taking into account their interaction.
We also conducted a supplementary analysis restricted to subjects who were not following a
drug therapy for controlling cardio-metabolic risk factors (n = 4800). The associations of BMI
and ABSI with each cardio-metabolic risk factor remained very similar (S1 Table).
The sign of the interaction between ABSI and high BMI category was negative for low HDL
and high fasting glucose, implying that a given increment of ABSI increases risk relatively more
for less heavy people (Tables 4 and 6, S2 and S4 Figs). By contrast, the interaction coefficient
Table 2. (Continued)
Women Men Total
N % N % N %
Metabolic syndrome score (including use of drugs)
0 1046 23.9 146 8.6 1192 19.6
1 1257 28.7 293 17.3 1550 25.5
2 1137 25.9 439 25.9 1576 25.9
3 674 15.4 474 27.9 1148 18.9
4 203 4.6 262 15.4 465 7.6
5 67 1.5 83 4.9 150 2.5
Metabolic syndrome (including use of drugs)
No 3440 78.5 878 51.7 4318 71
Yes 944 21.5 819 48.3 1763 29
Statins
No 4221 96.3 1574 92.8 5795 95.3
Yes 163 3.7 123 7.2 286 4.7
https://doi.org/10.1371/journal.pone.0185013.t002
ABSI and cardio-metabolic risk factors
PLOS ONE | https://doi.org/10.1371/journal.pone.0185013 September 25, 2017 6 / 15
was positive for VAT, implying that high ABSI affects VAT more when BMI is also high
(Table 7, S5 Fig).
Discussion
In the present study, we tested the separate and the joint contribution of ABSI and BMI to
high triglycerides, low HDL, high blood pressure, high fasting glucose and VAT, taking into
Table 3. Generalized linear models developed for studying the association between ABSI, BMI and high triglycerides.
High triglycerides OR triglyceride-lowering drugs
A1 A2 A3 A4
ABSI
ABSI (SDS NHANES) 0.36* 0.26*** 0.28***
[0.07,0.65] [0.17,0.34] [0.19,0.36]
BMI classes
Normal weight Ref. Ref. Ref.
Overweight 0.68*** 0.70*** 0.73***
[0.42,0.95] [0.44,0.96] [0.47,0.99]
Obesity 1 1.19*** 1.20*** 1.24***
[0.92,1.45] [0.94,1.46] [0.97,1.50]
Obesity 2 and 3 1.35*** 1.38*** 1.39***
[1.06,1.64] [1.09,1.67] [1.11,1.68]
BMI-ABSI interaction
Normal # ABSI (SDS NHANES) Ref.
Overweight # ABSI (SDS NHANES) 0.00
[-0.32,0.33]
Obesity 1 # ABSI (SDS NHANES) -0.13
[-0.46,0.19]
Obesity 2 and 3 # ABSI (SDS NHANES) -0.30
[-0.65,0.06]
Age classes
19 to 29 years Ref. Ref. Ref. Ref.
30 to 39 years -0.08 -0.07 -0.08 -0.05
[-0.39,0.24] [-0.39,0.25] [-0.39,0.23] [-0.36,0.27]
40 to 49 years 0.11 0.12 0.15 0.15
[-0.19,0.40] [-0.18,0.41] [-0.14,0.44] [-0.14,0.44]
50 to 59 years 0.24 0.24 0.32* 0.28
[-0.06,0.53] [-0.06,0.54] [0.03,0.62] [-0.02,0.57]
60 to 69 years 0.40* 0.42** 0.56*** 0.43**
[0.08,0.71] [0.10,0.73] [0.25,0.87] [0.12,0.74]
70 to 76 years 0.47* 0.49* 0.66** 0.49*
[0.06,0.89] [0.07,0.90] [0.24,1.07] [0.08,0.90]
Sex
Women Ref. Ref. Ref. Ref.
Men 1.06*** 1.05*** 1.21*** 1.13***
[0.92,1.21] [0.91,1.20] [1.07,1.35] [0.99,1.27]
Constant -2.90*** -2.91*** -2.16*** -3.01***
[-3.24,-2.55] [-3.26,-2.57] [-2.43,-1.89] [-3.35,-2.68]
Observations 6081 6081 6081 6081
BIC 5281 5261 5370 5286
https://doi.org/10.1371/journal.pone.0185013.t003
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account the effects of sex and age. We found that ABSI was independently associated with all
outcomes. Moreover, the joint use of BMI and ABSI was associated with a better estimate of
the probability of having high triglycerides, low HDL and high fasting glucose and of VAT
thickness as compared to BMI or ABSI alone. Interestingly, an ABSIBMI interaction was
detected for low HDL, high fasting glucose and VAT. These findings did not change when we
restricted the analysis to subjects who were not following a drug therapy for controlling the
cardio-metabolic risk factors.
Table 4. Generalized linear models developed for studying the association between ABSI, BMI and low HDL.
Low HDL
B1 B2 B3 B4
ABSI
ABSI (SDS NHANES) 0.54*** 0.19*** 0.21***
[0.26,0.81] [0.10,0.27] [0.12,0.29]
BMI classes
Normal Ref. Ref. Ref.
Overweight 0.73*** 0.79*** 0.81***
[0.48,0.98] [0.54,1.04] [0.56,1.06]
Obesity 1 1.32*** 1.38*** 1.41***
[1.06,1.57] [1.12,1.63] [1.15,1.66]
Obesity 2 and 3 1.58*** 1.66*** 1.67***
[1.30,1.86] [1.39,1.94] [1.40,1.95]
BMI-ABSI interaction
Normal # ABSI (SDS NHANES) Ref.
Overweight # ABSI (SDS NHANES) -0.35*
[-0.66,-0.04]
Obesity 1 # ABSI (SDS NHANES) -0.35*
[-0.66,-0.04]
Obesity 2 and 3 # ABSI (SDS NHANES) -0.53**
[-0.86,-0.19]
Age classes
19 to 29 years Ref. Ref. Ref. Ref.
30 to 39 years 0.04 0.05 0.05 0.07
[-0.24,0.31] [-0.22,0.32] [-0.21,0.32] [-0.20,0.35]
40 to 49 years -0.24 -0.22 -0.16 -0.18
[-0.50,0.02] [-0.48,0.04] [-0.42,0.09] [-0.44,0.08]
50 to 59 years -0.44** -0.42** -0.30* -0.38**
[-0.71,-0.16] [-0.70,-0.15] [-0.56,-0.03] [-0.65,-0.11]
60 to 69 years -0.48** -0.45** -0.24 -0.43**
[-0.78,-0.18] [-0.75,-0.15] [-0.53,0.05] [-0.73,-0.13]
70 to 76 years -0.48* -0.46* -0.22 -0.44*
[-0.91,-0.05] [-0.89,-0.03] [-0.64,0.20] [-0.87,-0.01]
Sex
Women Ref. Ref. Ref. Ref.
Men 0.17* 0.16* 0.36*** 0.22**
[0.02,0.32] [0.01,0.31] [0.21,0.51] [0.08,0.37]
Constant -2.30*** -2.37*** -1.52*** -2.47***
[-2.61,-2.00] [-2.68,-2.07] [-1.75,-1.29] [-2.77,-2.17]
Observations 6081 6081 6081 6081
BIC 5388 5371 5552 5381
https://doi.org/10.1371/journal.pone.0185013.t004
ABSI and cardio-metabolic risk factors
PLOS ONE | https://doi.org/10.1371/journal.pone.0185013 September 25, 2017 8 / 15
The greatest strength of this study is that it was performed at a single clinical research center
in a very large population of subjects with strictly standardized methods. Another strength of
this study is that the large number of enrolled subjects allowed to estimate relatively precisely
the degree of statistical interaction between ABSI and BMI and therefore to assess whether
these anthropometric measures associate independently with CMD risk factors.
Table 5. Generalized linear models developed for studying the association between ABSI, BMI and high blood pressure.
High blood pressure OR blood pressure-lowering drugs
C1 C2 C3 C4
ABSI
ABSI (SDS NHANES) 0.18 0.11** 0.13***
[-0.00,0.37] [0.04,0.19] [0.06,0.20]
BMI classes
Normal weight Ref. Ref. Ref.
Overweight 0.66*** 0.68*** 0.69***
[0.48,0.84] [0.51,0.86] [0.52,0.87]
Obesity 1 1.43*** 1.45*** 1.46***
[1.24,1.62] [1.26,1.63] [1.28,1.65]
Obesity 2 and 3 2.32*** 2.34*** 2.34***
[2.07,2.57] [2.10,2.57] [2.10,2.58]
BMI-ABSI interaction
Normal # ABSI (SDS NHANES) Ref.
Overweight # ABSI (SDS NHANES) -0.12
[-0.34,0.10]
Obesity 1 # ABSI (SDS NHANES) -0.03
[-0.26,0.20]
Obesity 2 and 3 # ABSI (SDS NHANES) -0.07
[-0.36,0.22]
Age classes
19 to 29 years Ref. Ref. Ref. Ref.
30 to 39 years 0.34* 0.34* 0.31* 0.35*
[0.07,0.60] [0.07,0.60] [0.06,0.56] [0.08,0.61]
40 to 49 years 1.03*** 1.03*** 0.99*** 1.05***
[0.78,1.28] [0.78,1.28] [0.75,1.23] [0.80,1.30]
50 to 59 years 1.70*** 1.70*** 1.68*** 1.73***
[1.45,1.96] [1.45,1.96] [1.44,1.93] [1.47,1.98]
60 to 69 years 2.51*** 2.51*** 2.56*** 2.53***
[2.22,2.80] [2.22,2.80] [2.28,2.83] [2.24,2.81]
70 to 76 years 3.15*** 3.16*** 3.23*** 3.16***
[2.69,3.62] [2.70,3.62] [2.78,3.68] [2.70,3.62]
Sex
Women Ref. Ref. Ref. Ref.
Men 1.27*** 1.27*** 1.44*** 1.31***
[1.13,1.41] [1.13,1.42] [1.30,1.57] [1.17,1.45]
Constant -2.53*** -2.55*** -1.61*** -2.60***
[-2.80,-2.26] [-2.82,-2.28] [-1.83,-1.39] [-2.87,-2.33]
Observations 6081 6081 6081 6081
BIC 6605 6580 7093 6580
https://doi.org/10.1371/journal.pone.0185013.t005
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Table 6. Generalized linear models developed for studying the association between ABSI, BMI and high blood glucose.
High blood glucose OR glucose-lowering drugs
D1 D2 D3 D4
ABSI
ABSI (SDS NHANES) 0.33** 0.17*** 0.17***
[0.10,0.56] [0.09,0.24] [0.10,0.25]
BMI classes
Normal Ref. Ref. Ref.
Overweight 0.55*** 0.57*** 0.58***
[0.34,0.75] [0.36,0.77] [0.38,0.79]
Obesity 1 1.05*** 1.08*** 1.10***
[0.84,1.27] [0.87,1.29] [0.89,1.31]
Obesity 2 and 3 1.57*** 1.63*** 1.64***
[1.33,1.81] [1.40,1.87] [1.40,1.87]
BMI-ABSI interaction
Normal # ABSI (SDS NHANES) Ref.
Overweight # ABSI (SDS NHANES) -0.06
[-0.32,0.20]
Obesity 1 # ABSI (SDS NHANES) -0.22
[-0.49,0.04]
Obesity 2 and 3 # ABSI (SDS NHANES) -0.38*
[-0.67,-0.08]
Age classes
19 to 29 years Ref. Ref. Ref. Ref.
30 to 39 years 0.51** 0.52** 0.51** 0.53**
[0.16,0.87] [0.16,0.88] [0.15,0.86] [0.18,0.89]
40 to 49 years 1.17*** 1.18*** 1.18*** 1.20***
[0.83,1.50] [0.84,1.51] [0.85,1.51] [0.86,1.53]
50 to 59 years 1.81*** 1.82*** 1.85*** 1.84***
[1.48,2.15] [1.49,2.16] [1.52,2.18] [1.51,2.17]
60 to 69 years 2.07*** 2.09*** 2.20*** 2.10***
[1.72,2.41] [1.74,2.43] [1.86,2.54] [1.75,2.44]
70 to 76 years 2.19*** 2.20*** 2.33*** 2.20***
[1.77,2.61] [1.78,2.62] [1.91,2.74] [1.78,2.62]
Sex
Women Ref. Ref. Ref. Ref.
Men 0.91*** 0.89*** 1.05*** 0.94***
[0.78,1.04] [0.76,1.03] [0.92,1.17] [0.81,1.07]
Constant -3.30*** -3.33*** -2.61*** -3.39***
[-3.66,-2.94] [-3.69,-2.98] [-2.93,-2.30] [-3.75,-3.04]
Observations 6081 6081 6081 6081
BIC 6343 6328 6547 6337
Values are regression coefficients, 95% confidence intervals in brackets and BIC.
Model 1: ABSI (continuous), BMI (discrete), ABSIBMI interaction (continuous X discrete), sex (discrete), age (discrete).
Model 2: same as #1 without the ABSIBMI interaction.
Model 3: same as #2 without BMI.
Model 4: same as #2 without ABSI.
Abbreviations: Ref = Reference category (regression coefficient = 0)
* p<0.05
** p<0.01
*** p<0.001
https://doi.org/10.1371/journal.pone.0185013.t006
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Table 7. Generalized linear models developed for studying the association between ABSI, BMI and VAT.
VAT
E1 E2 E3 E4
ABSI
ABSI (SDS NHANES) 0.24*** 0.62*** 0.65***
[0.13,0.35] [0.57,0.67] [0.59,0.72]
BMI classes
Normal weight Ref. Ref. Ref.
Overweight 1.07*** 0.95*** 1.02***
[0.96,1.19] [0.83,1.06] [0.91,1.14]
Obesity 1 2.49*** 2.34*** 2.44***
[2.37,2.62] [2.22,2.46] [2.32,2.57]
Obesity 2 and 3 4.50*** 4.34*** 4.38***
[4.35,4.65] [4.19,4.48] [4.22,4.53]
BMI-ABSI interaction
Normal # ABSI (SDS NHANES) Ref.
Overweight # ABSI (SDS NHANES) 0.35***
[0.22,0.49]
Obesity 1 # ABSI (SDS NHANES) 0.61***
[0.46,0.75]
Obesity 2 and 3 # ABSI (SDS NHANES) 0.55***
[0.38,0.73]
Age classes
19 to 29 years Ref. Ref. Ref. Ref.
30 to 39 years 0.31*** 0.28*** 0.32** 0.39***
[0.15,0.47] [0.11,0.44] [0.11,0.53] [0.22,0.56]
40 to 49 years 0.81*** 0.76*** 0.90*** 0.93***
[0.65,0.96] [0.61,0.92] [0.70,1.10] [0.77,1.09]
50 to 59 years 1.33*** 1.29*** 1.57*** 1.47***
[1.17,1.49] [1.13,1.45] [1.37,1.78] [1.30,1.64]
60 to 69 years 1.88*** 1.82*** 2.35*** 1.95***
[1.70,2.05] [1.64,1.99] [2.13,2.57] [1.77,2.14]
70 to 76 years 2.38*** 2.33*** 2.87*** 2.43***
[2.14,2.63] [2.08,2.57] [2.55,3.19] [2.17,2.69]
Sex
Women Ref. Ref. Ref. Ref.
Men 2.05*** 2.08*** 2.58*** 2.29***
[1.96,2.15] [1.99,2.18] [2.46,2.69] [2.19,2.38]
Constant 2.33*** 2.49*** 3.71*** 2.13***
[2.17,2.49] [2.33,2.64] [3.53,3.89] [1.97,2.29]
Observations 6081 6081 6081 6081
BIC 22882 22930 26044 23479
Values are regression coefficients, 95% confidence intervals in brackets and BIC.
Model 1: ABSI (continuous), BMI (discrete), ABSIBMI interaction (continuous X discrete), sex (discrete), age (discrete).
Model 2: same as #1 without the ABSIBMI interaction.
Model 3: same as #2 without BMI.
Model 4: same as #2 without ABSI.* p<0.05
** p<0.01
*** p<0.001
https://doi.org/10.1371/journal.pone.0185013.t007
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Among the study limitations are the following. First, we studied a self-selected sample of
Caucasian adults and our findings are not necessarily applicable to other populations. Second,
we measured WC at the WHO landmark and not at the NHANES landmark. Although the
WC measures obtained at the WHO and NHANES landmarks are well correlated, this may
have produced some misclassification of ABSI [35]. Third, VAT was measured by US, which is
not a reference method. However, the US measurement procedure has been thoroughly vali-
dated against computed tomography [29, 36] and used in previous studies [25, 30, 31, 37].
WC, a surrogate measure of abdominal adiposity, is an established risk factor for CMD, but
its strong association with BMI makes it difficult to assess its independent contribution to
CMD [1, 12]. By standardizing WC on its value estimated from allometric regression of weight
and height, ABSI offers a WC measure which is independent from weight and BMI, allowing
the joint use of BMI and WC to study CMD [1, 38, 39]. Thus, ABSI has great potential for
being used in place of WC and together with BMI to evaluate the independent contributions
of body mass and shape on CVD [10, 11].
In a cross-sectional study of subjects with type 2 diabetes mellitus, ABSI was associated with
visceral fat area estimated by bioelectrical impedance analysis [17]. Using US to directly mea-
sure VAT thickness, the present study confirms that ABSI is directly associated with VAT and
is thus a surrogate measure of abdominal adiposity. The association that we detected between
ABSI and VAT supports the association ABSI to CMD risk factors. Such association might
also partly explain the observed association of ABSI with overall mortality [1, 38, 39].
In a large cross-sectional study performed in Iran, BMI and the waist-to-height ratio were
stronger than ABSI at predicting CVD risk factors [13]. One cross-sectional study and one
cohort study reported a modest association between ABSI and hypertension and hypercholes-
terolemia [14, 15]. Unfortunately, these studies did not evaluate the joint contribution of ABSI
and BMI to CMD risk factors. Our study confirms that ABSI taken alone is less accurate than
BMI at detecting CMD risk factors, but it also shows that the joint use of ABSI and BMI is
superior to BMI (and ABSI) to identify the occurrence of low HDL, high triglycerides and high
glucose.
Conclusion
In conclusion, ABSI is associated with all the components of the MS and with VAT thickness.
The joint use of ABSI and BMI allows a better assessment of the probability of low HDL, high
triglycerides and high fasting glucose and of VAT thickness as compared to BMI alone. ABSI
can be a useful index, as opposed to WC, for evaluating the relative contribution of central
obesity to clinical outcomes in complement with and not as an alternative to BMI. Further
studies aimed to evaluate the capability of ABSI-BMI to jointly predict longitudinal outcomes
are warranted.
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